Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Depreciation & Amortization (CF) (2016 - 2026)

Champions Oncology has reported Depreciation & Amortization (CF) over the past 17 years, most recently at $341000.0 for Q1 2026.

  • Quarterly results put Depreciation & Amortization (CF) at $341000.0 for Q1 2026, down 14.32% from a year ago — trailing twelve months through Jan 2026 was $1.4 million (down 14.86% YoY), and the annual figure for FY2025 was $1.6 million, down 12.16%.
  • Depreciation & Amortization (CF) for Q1 2026 was $341000.0 at Champions Oncology, down from $357000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for CSBR hit a ceiling of $583000.0 in Q2 2023 and a floor of $341000.0 in Q1 2026.
  • Median Depreciation & Amortization (CF) over the past 5 years was $449000.0 (2024), compared with a mean of $457235.3.
  • Biggest five-year swings in Depreciation & Amortization (CF): surged 87.46% in 2022 and later fell 21.61% in 2024.
  • Champions Oncology's Depreciation & Amortization (CF) stood at $560000.0 in 2022, then decreased by 13.57% to $484000.0 in 2023, then fell by 17.56% to $399000.0 in 2024, then decreased by 10.53% to $357000.0 in 2025, then decreased by 4.48% to $341000.0 in 2026.
  • The last three reported values for Depreciation & Amortization (CF) were $341000.0 (Q1 2026), $357000.0 (Q4 2025), and $358000.0 (Q3 2025) per Business Quant data.